The patent includes claims related to the reduced food effect of Cip-Isotretioin relative to currently marketed formulations, the company said.
Larry Andrews, president and CEO of Cipher, said: “Having the US patent allowed represents an important milestone on our path to commercialization for Cip-Isotretinoin. It also reinforces that the product is truly differentiated from currently marketed formulations.”